Host |
Mouse |
Klon |
DBM15.52 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
- |
Isotyp |
IgG2a kappa |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15
|
Diagnostic Biosystems |
DBM15.52 |
6 ml |
Ready-to-use |
CE/IVD |
PDM261 |
-
|
Host |
Mouse |
Klon |
DBM15.52 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Breast carcinoma |
Verdünnung |
- |
Isotyp |
IgG2a kappa |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15
|
Diagnostic Biosystems |
DBM15.52 |
25 ml |
Ready-to-use |
CE/IVD |
PDM261-25 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM23 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin and breast. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15 (Gross Cystic Disease Fluid Protein, BRST-2)
|
Zeta Corporation |
ZM23 |
1 ml |
Concentrate |
CE/IVD |
Z2345ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM23 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin and breast. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15 (Gross Cystic Disease Fluid Protein, BRST-2)
|
Zeta Corporation |
ZM23 |
7 ml |
Ready-to-use |
CE/IVD |
Z2345MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM23 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin and breast. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15 (Gross Cystic Disease Fluid Protein, BRST-2)
|
Zeta Corporation |
ZM23 |
0.5 ml |
Concentrate |
CE/IVD |
Z2345MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM23 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Skin and breast. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human GCDFP-15 protein fragment (aa 41-146) |
Lokalisation |
Cytoplasm |
GCDFP-15 (Gross Cystic Disease Fluid Protein, BRST-2)
|
Zeta Corporation |
ZM23 |
0.1 ml |
Concentrate |
CE/IVD |
Z2345MT |
-
|
Host |
Mouse+Rabbit |
Klon |
D6+31A5 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast |
Verdünnung |
- |
Isotyp |
Mouse IgG2a+Rabbit IgG |
Lokalisation |
Cytoplasmic |
GCDFP-15 + Mammaglobin
|
Biocare Medical |
D6+31A5 |
6 ml |
Ready-to-use |
CE/IVD |
PM317DSAA |
-
|
Host |
Mouse |
Klon |
GA-5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Native GFAP purified from pig spinal cord |
Lokalisation |
Cytoplasm |
GFAP
|
Zeta Corporation |
GA-5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2255ML |
-
|
Host |
Mouse |
Klon |
GA-5 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Native GFAP purified from pig spinal cord |
Lokalisation |
Cytoplasm |
GFAP
|
Zeta Corporation |
GA-5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2255MP |
-
|
Host |
Mouse |
Klon |
GA-5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Native GFAP purified from pig spinal cord |
Lokalisation |
Cytoplasm |
GFAP
|
Zeta Corporation |
GA-5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2255MS |
-
|
Host |
Mouse |
Klon |
GA-5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Brain or astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Native GFAP purified from pig spinal cord |
Lokalisation |
Cytoplasm |
GFAP
|
Zeta Corporation |
GA-5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2255MT |
-
|
Host |
Mouse |
Klon |
GF-05 |
Format |
Purified |
Methode |
WB, EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native glial fibriallary acidic protein |
GFAP (Glial Fibrillary Acidic Protein)
|
Zytomed Systems GmbH |
GF-05 |
200 µg |
Purified |
RUO |
607-0049 |
-
|
Host |
Mouse |
Klon |
GA5 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
GA5 |
1 ml |
Concentrate |
CE/IVD |
MOB064 |
-
|
Host |
Mouse |
Klon |
GA5 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
GA5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB064-01 |
-
|
Host |
Mouse |
Klon |
GA5 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
GA5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB064-05 |
-
|
Host |
Mouse |
Klon |
GA5 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
GA5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM008 |
-
|
Host |
Mouse |
Klon |
GA5 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
GA5 |
25 ml |
Ready-to-use |
CE/IVD |
PDM008-25 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR028 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:250 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP014 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:250 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP014-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:250 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
GFAP (Glial Fibrillary Acidic Protein)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP014-05 |
-
|
Host |
Mouse |
Klon |
6271 |
Format |
Purified |
Methode |
EL, IF |
Isotyp |
Mouse IgG3 |
Verdünnung |
Giarda lamblia cysts |
Giardia lamblia
|
Zytomed Systems GmbH |
6271 |
100 µg |
Purified |
RUO |
607-0064 |
-
|
Host |
Rabbit |
Klon |
CAL8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane and cytoplasm |
GITR
|
Biocare Medical |
CAL8 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3221A |
-
|
Host |
Rabbit |
Klon |
CAL8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane and cytoplasm |
GITR
|
Biocare Medical |
CAL8 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3221B |
-
|
Host |
Rabbit |
Klon |
CAL8 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane and cytoplasm |
GITR
|
Biocare Medical |
CAL8 |
6 ml |
Ready-to-use |
CE/IVD |
API3221AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
concentrate |
Methode |
P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
nuclear |
Glucagon
|
Biocare Medical |
polyclonal |
0.1 ml |
concentrate |
CE/IVD |
ACI3276A |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
concentrate |
Methode |
P |
Positivkontrolle |
Pancreas |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
nuclear |
Glucagon
|
Biocare Medical |
polyclonal |
1 ml |
concentrate |
CE/IVD |
ACI3276C |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Pancreas |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
nuclear |
Glucagon
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3276AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Pancreas |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
nucear |
Glucagon
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
AVI3276G |
-
|
Host |
Rabbit |
Klon |
EP74 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) |
Lokalisation |
Cytoplasm |
Glucagon
|
Zeta Corporation |
EP74 |
1 ml |
Concentrate |
CE/IVD |
Z2299RL |
-
|
Host |
Rabbit |
Klon |
EP74 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) |
Lokalisation |
Cytoplasm |
Glucagon
|
Zeta Corporation |
EP74 |
7 ml |
Ready-to-use |
CE/IVD |
Z2299RP |
-
|
Host |
Rabbit |
Klon |
EP74 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) |
Lokalisation |
Cytoplasm |
Glucagon
|
Zeta Corporation |
EP74 |
0.5 ml |
Concentrate |
CE/IVD |
Z2299RS |
-
|
Host |
Rabbit |
Klon |
EP74 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal pancreas. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) |
Lokalisation |
Cytoplasm |
Glucagon
|
Zeta Corporation |
EP74 |
0.1 ml |
Concentrate |
CE/IVD |
Z2299RT |
-
|
Host |
Mouse |
Klon |
ZM137 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZM137 |
1 ml |
Concentrate |
CE/IVD |
Z2448ML |
-
|
Host |
Mouse |
Klon |
ZM137 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZM137 |
7 ml |
Ready-to-use |
CE/IVD |
Z2448MP |
-
|
Host |
Mouse |
Klon |
ZM137 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZM137 |
0.5 ml |
Concentrate |
CE/IVD |
Z2448MS |
-
|
Host |
Mouse |
Klon |
ZM137 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZM137 |
0.1 ml |
Concentrate |
CE/IVD |
Z2448MT |
-
|
Host |
Rabbit |
Klon |
ZR308 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZR308 |
1 ml |
Concentrate |
CE/IVD |
Z2585RL |
-
|
Host |
Rabbit |
Klon |
ZR308 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZR308 |
7 ml |
Ready-to-use |
CE/IVD |
Z2585RP |
-
|
Host |
Rabbit |
Klon |
ZR308 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZR308 |
0.5 ml |
Concentrate |
CE/IVD |
Z2585RS |
-
|
Host |
Rabbit |
Klon |
ZR308 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human full-length GLUT-1 protein |
Lokalisation |
Cell membrane |
GLUT-1
|
Zeta Corporation |
ZR308 |
0.1 ml |
Concentrate |
CE/IVD |
Z2585RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
GLUT-1 (Glucose Transporter 1)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
RUO |
RP128 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
GLUT-1 (Glucose Transporter 1)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
RUO |
RP128-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
GLUT-1 (Glucose Transporter 1)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RP128-05 |
-
|
Host |
Mouse |
Klon |
1F8 |
Format |
Purified |
Methode |
F, WB, IF, IP |
Isotyp |
Mouse IgG1 |
Verdünnung |
Partially purified vesicles |
GLUT 4 (Glucose Transporter 4)
|
Zytomed Systems GmbH |
1F8 |
50 µg |
Purified |
RUO |
607-0112 |
-
|
Host |
Mouse |
Klon |
6/Glutamine Synthetase |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal |
Positivkontrolle |
Hepatocellular carcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG2a |
Lokalisation |
Cytoplasm |
Glutamine Synthetase
|
Biocare Medical |
6/Glutamine Synthetase |
0.1 ml |
Concentrate |
CE/IVD |
ACI3009A |
-
|
Host |
Mouse |
Klon |
6/Glutamine Synthetase |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal |
Positivkontrolle |
Hepatocellular carcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG2 |
Lokalisation |
Cytoplasm |
Glutamine Synthetase
|
Biocare Medical |
6/Glutamine Synthetase |
0.5 ml |
Concentrate |
CE/IVD |
ACI3009B |
-
|
Host |
Mouse |
Klon |
6/Glutamine Synthetase |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal |
Positivkontrolle |
Hepatocellular carcinoma |
Verdünnung |
- |
Isotyp |
IgG2a |
Lokalisation |
Cytoplasm |
Glutamine Synthetase
|
Biocare Medical |
6/Glutamine Synthetase |
6 ml |
Ready-to-use |
CE/IVD |
API3009AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
WB |
Verdünnung |
0,5 - 1 µg/mL |
Isotyp |
Rabbit IgG |
Verdünnung |
A 16 amino acid peptide located near human GAPDH carboxy-terminus |
Glyceraldehyde 3-Phosphate Dehydrogenase (GAPD, GAPDH)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
607-0143 |
-
|
Host |
Mouse |
Klon |
JC159 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
Glycophorin A (CD235a)
|
Diagnostic Biosystems |
JC159 |
1 ml |
Concentrate |
CE/IVD |
MOB066 |
-
|